Copyright Reports & Markets. All rights reserved.

Global Hip Osteoarthritis Pain Medicine Market Research Report 2021

Request for Sample of this report
Buy now

1 Hip Osteoarthritis Pain Medicine Market Overview

  • 1.1 Product Overview and Scope of Hip Osteoarthritis Pain Medicine
  • 1.2 Hip Osteoarthritis Pain Medicine Segment by Type
    • 1.2.1 Global Hip Osteoarthritis Pain Medicine Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Oral
    • 1.2.3 Injection
    • 1.2.4 External
  • 1.3 Hip Osteoarthritis Pain Medicine Segment by Application
    • 1.3.1 Hip Osteoarthritis Pain Medicine Sales Comparison by Application: (2021-2027)
    • 1.3.2 Medical Care
    • 1.3.3 Personal Care
  • 1.4 Global Hip Osteoarthritis Pain Medicine Market Size Estimates and Forecasts
    • 1.4.1 Global Hip Osteoarthritis Pain Medicine Revenue 2016-2027
    • 1.4.2 Global Hip Osteoarthritis Pain Medicine Sales 2016-2027
    • 1.4.3 Hip Osteoarthritis Pain Medicine Market Size by Region: 2016 Versus 2021 Versus 2027

2 Hip Osteoarthritis Pain Medicine Market Competition by Manufacturers

  • 2.1 Global Hip Osteoarthritis Pain Medicine Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global Hip Osteoarthritis Pain Medicine Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global Hip Osteoarthritis Pain Medicine Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers Hip Osteoarthritis Pain Medicine Manufacturing Sites, Area Served, Product Type
  • 2.5 Hip Osteoarthritis Pain Medicine Market Competitive Situation and Trends
    • 2.5.1 Hip Osteoarthritis Pain Medicine Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest Hip Osteoarthritis Pain Medicine Players Market Share by Revenue
    • 2.5.3 Global Hip Osteoarthritis Pain Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Hip Osteoarthritis Pain Medicine Retrospective Market Scenario by Region

  • 3.1 Global Hip Osteoarthritis Pain Medicine Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.2 Global Hip Osteoarthritis Pain Medicine Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.3 North America Hip Osteoarthritis Pain Medicine Market Facts & Figures by Country
    • 3.3.1 North America Hip Osteoarthritis Pain Medicine Sales by Country
    • 3.3.2 North America Hip Osteoarthritis Pain Medicine Revenue by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe Hip Osteoarthritis Pain Medicine Market Facts & Figures by Country
    • 3.4.1 Europe Hip Osteoarthritis Pain Medicine Sales by Country
    • 3.4.2 Europe Hip Osteoarthritis Pain Medicine Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Hip Osteoarthritis Pain Medicine Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Hip Osteoarthritis Pain Medicine Sales by Region
    • 3.5.2 Asia Pacific Hip Osteoarthritis Pain Medicine Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America Hip Osteoarthritis Pain Medicine Market Facts & Figures by Country
    • 3.6.1 Latin America Hip Osteoarthritis Pain Medicine Sales by Country
    • 3.6.2 Latin America Hip Osteoarthritis Pain Medicine Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Hip Osteoarthritis Pain Medicine Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Hip Osteoarthritis Pain Medicine Sales by Country
    • 3.7.2 Middle East and Africa Hip Osteoarthritis Pain Medicine Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 UAE

4 Global Hip Osteoarthritis Pain Medicine Historic Market Analysis by Type

  • 4.1 Global Hip Osteoarthritis Pain Medicine Sales Market Share by Type (2016-2021)
  • 4.2 Global Hip Osteoarthritis Pain Medicine Revenue Market Share by Type (2016-2021)
  • 4.3 Global Hip Osteoarthritis Pain Medicine Price by Type (2016-2021)

5 Global Hip Osteoarthritis Pain Medicine Historic Market Analysis by Application

  • 5.1 Global Hip Osteoarthritis Pain Medicine Sales Market Share by Application (2016-2021)
  • 5.2 Global Hip Osteoarthritis Pain Medicine Revenue Market Share by Application (2016-2021)
  • 5.3 Global Hip Osteoarthritis Pain Medicine Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Pfizer
    • 6.1.1 Pfizer Corporation Information
    • 6.1.2 Pfizer Description and Business Overview
    • 6.1.3 Pfizer Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Pfizer Product Portfolio
    • 6.1.5 Pfizer Recent Developments/Updates
  • 6.2 Johnson and Johnson
    • 6.2.1 Johnson and Johnson Corporation Information
    • 6.2.2 Johnson and Johnson Description and Business Overview
    • 6.2.3 Johnson and Johnson Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Johnson and Johnson Product Portfolio
    • 6.2.5 Johnson and Johnson Recent Developments/Updates
  • 6.3 GlaxoSmithKline
    • 6.3.1 GlaxoSmithKline Corporation Information
    • 6.3.2 GlaxoSmithKline Description and Business Overview
    • 6.3.3 GlaxoSmithKline Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 GlaxoSmithKline Product Portfolio
    • 6.3.5 GlaxoSmithKline Recent Developments/Updates
  • 6.4 Bayer
    • 6.4.1 Bayer Corporation Information
    • 6.4.2 Bayer Description and Business Overview
    • 6.4.3 Bayer Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Bayer Product Portfolio
    • 6.4.5 Bayer Recent Developments/Updates
  • 6.5 Eli Lilly
    • 6.5.1 Eli Lilly Corporation Information
    • 6.5.2 Eli Lilly Description and Business Overview
    • 6.5.3 Eli Lilly Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Eli Lilly Product Portfolio
    • 6.5.5 Eli Lilly Recent Developments/Updates
  • 6.6 Novartis
    • 6.6.1 Novartis Corporation Information
    • 6.6.2 Novartis Description and Business Overview
    • 6.6.3 Novartis Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 Novartis Product Portfolio
    • 6.6.5 Novartis Recent Developments/Updates
  • 6.7 Sanofi
    • 6.6.1 Sanofi Corporation Information
    • 6.6.2 Sanofi Description and Business Overview
    • 6.6.3 Sanofi Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Sanofi Product Portfolio
    • 6.7.5 Sanofi Recent Developments/Updates
  • 6.8 Horizon Pharma
    • 6.8.1 Horizon Pharma Corporation Information
    • 6.8.2 Horizon Pharma Description and Business Overview
    • 6.8.3 Horizon Pharma Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 Horizon Pharma Product Portfolio
    • 6.8.5 Horizon Pharma Recent Developments/Updates
  • 6.9 Abbott
    • 6.9.1 Abbott Corporation Information
    • 6.9.2 Abbott Description and Business Overview
    • 6.9.3 Abbott Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 Abbott Product Portfolio
    • 6.9.5 Abbott Recent Developments/Updates
  • 6.10 Mylan
    • 6.10.1 Mylan Corporation Information
    • 6.10.2 Mylan Description and Business Overview
    • 6.10.3 Mylan Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 Mylan Product Portfolio
    • 6.10.5 Mylan Recent Developments/Updates
  • 6.11 Daiichi Sankyo
    • 6.11.1 Daiichi Sankyo Corporation Information
    • 6.11.2 Daiichi Sankyo Hip Osteoarthritis Pain Medicine Description and Business Overview
    • 6.11.3 Daiichi Sankyo Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.11.4 Daiichi Sankyo Product Portfolio
    • 6.11.5 Daiichi Sankyo Recent Developments/Updates
  • 6.12 TEVA
    • 6.12.1 TEVA Corporation Information
    • 6.12.2 TEVA Hip Osteoarthritis Pain Medicine Description and Business Overview
    • 6.12.3 TEVA Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.12.4 TEVA Product Portfolio
    • 6.12.5 TEVA Recent Developments/Updates
  • 6.13 Almatica Pharma
    • 6.13.1 Almatica Pharma Corporation Information
    • 6.13.2 Almatica Pharma Hip Osteoarthritis Pain Medicine Description and Business Overview
    • 6.13.3 Almatica Pharma Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.13.4 Almatica Pharma Product Portfolio
    • 6.13.5 Almatica Pharma Recent Developments/Updates
  • 6.14 Astellas Pharma
    • 6.14.1 Astellas Pharma Corporation Information
    • 6.14.2 Astellas Pharma Hip Osteoarthritis Pain Medicine Description and Business Overview
    • 6.14.3 Astellas Pharma Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.14.4 Astellas Pharma Product Portfolio
    • 6.14.5 Astellas Pharma Recent Developments/Updates
  • 6.15 Tide Pharmaceutical
    • 6.15.1 Tide Pharmaceutical Corporation Information
    • 6.15.2 Tide Pharmaceutical Hip Osteoarthritis Pain Medicine Description and Business Overview
    • 6.15.3 Tide Pharmaceutical Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.15.4 Tide Pharmaceutical Product Portfolio
    • 6.15.5 Tide Pharmaceutical Recent Developments/Updates
  • 6.16 Iroko Pharmaceuticals
    • 6.16.1 Iroko Pharmaceuticals Corporation Information
    • 6.16.2 Iroko Pharmaceuticals Hip Osteoarthritis Pain Medicine Description and Business Overview
    • 6.16.3 Iroko Pharmaceuticals Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.16.4 Iroko Pharmaceuticals Product Portfolio
    • 6.16.5 Iroko Pharmaceuticals Recent Developments/Updates
  • 6.17 Hengrui Pharmaceutical
    • 6.17.1 Hengrui Pharmaceutical Corporation Information
    • 6.17.2 Hengrui Pharmaceutical Hip Osteoarthritis Pain Medicine Description and Business Overview
    • 6.17.3 Hengrui Pharmaceutical Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.17.4 Hengrui Pharmaceutical Product Portfolio
    • 6.17.5 Hengrui Pharmaceutical Recent Developments/Updates
  • 6.18 Abiogen Pharma
    • 6.18.1 Abiogen Pharma Corporation Information
    • 6.18.2 Abiogen Pharma Hip Osteoarthritis Pain Medicine Description and Business Overview
    • 6.18.3 Abiogen Pharma Hip Osteoarthritis Pain Medicine Sales, Revenue and Gross Margin (2016-2021)
    • 6.18.4 Abiogen Pharma Product Portfolio
    • 6.18.5 Abiogen Pharma Recent Developments/Updates

7 Hip Osteoarthritis Pain Medicine Manufacturing Cost Analysis

  • 7.1 Hip Osteoarthritis Pain Medicine Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Hip Osteoarthritis Pain Medicine
  • 7.4 Hip Osteoarthritis Pain Medicine Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Hip Osteoarthritis Pain Medicine Distributors List
  • 8.3 Hip Osteoarthritis Pain Medicine Customers

9 Hip Osteoarthritis Pain Medicine Market Dynamics

  • 9.1 Hip Osteoarthritis Pain Medicine Industry Trends
  • 9.2 Hip Osteoarthritis Pain Medicine Growth Drivers
  • 9.3 Hip Osteoarthritis Pain Medicine Market Challenges
  • 9.4 Hip Osteoarthritis Pain Medicine Market Restraints

10 Global Market Forecast

  • 10.1 Hip Osteoarthritis Pain Medicine Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Hip Osteoarthritis Pain Medicine by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of Hip Osteoarthritis Pain Medicine by Type (2022-2027)
  • 10.2 Hip Osteoarthritis Pain Medicine Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Hip Osteoarthritis Pain Medicine by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of Hip Osteoarthritis Pain Medicine by Application (2022-2027)
  • 10.3 Hip Osteoarthritis Pain Medicine Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Hip Osteoarthritis Pain Medicine by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of Hip Osteoarthritis Pain Medicine by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Oral
    Injection
    External

    Segment by Application
    Medical Care
    Personal Care

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    By Company
    Pfizer
    Johnson and Johnson
    GlaxoSmithKline
    Bayer
    Eli Lilly
    Novartis
    Sanofi
    Horizon Pharma
    Abbott
    Mylan
    Daiichi Sankyo
    TEVA
    Almatica Pharma
    Astellas Pharma
    Tide Pharmaceutical
    Iroko Pharmaceuticals
    Hengrui Pharmaceutical
    Abiogen Pharma

    Buy now